Literature DB >> 23986346

Role of zoledronate in aromatase activity should be considered in future studies.

Mohamed Amin Ghobadifar.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23986346      PMCID： PMC3755941          DOI： 10.1634/theoncologist.2013-0208

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  6 in total

1.  Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

Authors:  H Eidtmann; R de Boer; N Bundred; A Llombart-Cussac; N Davidson; P Neven; G von Minckwitz; J Miller; N Schenk; R Coleman
Journal:  Ann Oncol       Date:  2010-05-05       Impact factor: 32.976

2.  Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

Authors:  Michael F X Gnant; Brigitte Mlineritsch; Gero Luschin-Ebengreuth; Stephan Grampp; Helmut Kaessmann; Marianne Schmid; Christian Menzel; Jutta Claudia Piswanger-Soelkner; Arik Galid; Martina Mittlboeck; Hubert Hausmaninger; Raimund Jakesz
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

3.  Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.

Authors:  Amanda J Schech; Brandon E Nemieboka; Angela H Brodie
Journal:  J Steroid Biochem Mol Biol       Date:  2012-06-01       Impact factor: 4.292

4.  Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.

Authors:  Antonis Valachis; Nikolaos P Polyzos; Robert E Coleman; Michael Gnant; Holger Eidtmann; Adam M Brufsky; Rebecca Aft; Amye J Tevaarwerk; Karen Swenson; Pehr Lind; Davide Mauri
Journal:  Oncologist       Date:  2013-02-12

5.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Authors:  Michael Gnant; Brigitte Mlineritsch; Gero Luschin-Ebengreuth; Franz Kainberger; Helmut Kässmann; Jutta Claudia Piswanger-Sölkner; Michael Seifert; Ferdinand Ploner; Christian Menzel; Peter Dubsky; Florian Fitzal; Vesna Bjelic-Radisic; Günther Steger; Richard Greil; Christian Marth; Ernst Kubista; Hellmut Samonigg; Peter Wohlmuth; Martina Mittlböck; Raimund Jakesz
Journal:  Lancet Oncol       Date:  2008-08-19       Impact factor: 41.316

6.  Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

Authors:  James E Lester; David Dodwell; Omprakash P Purohit; Sandra A Gutcher; Susan P Ellis; Ruth Thorpe; Janet M Horsman; Janet E Brown; Rosemary A Hannon; Robert E Coleman
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531
  6 in total
  1 in total

1.  In reply.

Authors:  Antonis Valachis; Nikolaos P Polyzos
Journal:  Oncologist       Date:  2013
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.